Can Magic Mushroom Companies Successfully Challenge 280E?

The question of whether psilocybin businesses can successfully challenge IRC Section 280E is not merely academic - it has real financial consequences for the growing number of operators in states like Oregon, Colorado, and others that have moved to regulate psilocybin services. The legal arguments are, in many ways, stronger than those being made in the cannabis context.

"Within the Meaning of" vs. "Listed As"

Section 280E denies deductions to businesses trafficking in controlled substances "as defined in schedule I and II of the Controlled Substances Act, as determined within the meaning of section 102 of such Act." The phrase "within the meaning of" is critical. It does not say "listed as" or "classified as" - it points to the definitional criteria of Section 102, which include factors like abuse potential, accepted medical use, and safety under medical supervision.

This distinction matters enormously. If a substance meets the criteria for a lower schedule based on current scientific evidence - even if the DEA has not yet formally rescheduled it - there is a strong argument that 280E should not apply.

Congressional Intent

A comparison of how Congress uses scheduling language across federal statutes is instructive. In 10 USC 912a (military drug law), Congress used the phrase "listed on a schedule of controlled substances." In 34 USC 10705 (grants for drug courts), similar "listed" language appears. But in Section 280E, Congress chose "within the meaning of" - suggesting a deliberate choice to tie the provision to substantive criteria rather than to the formal scheduling list itself.

Accepted Medical Use

The evidence for psilocybin's accepted medical use is substantial and growing. The FDA has granted Breakthrough Therapy designation to psilocybin-assisted therapy on two separate occasions. Johns Hopkins University and NYU have published landmark research demonstrating psilocybin's efficacy for treatment-resistant depression, end-of-life anxiety, and addiction.

Three states have now legalized regulated psilocybin services, creating frameworks that presuppose accepted medical and therapeutic utility.

Safety Profile

NIDA's own research characterizes psilocybin as having a "low level of toxicity." Unlike many Schedule I substances, psilocybin has no established lethal dose in humans, does not produce physical dependence, and has a remarkably low abuse potential. Research has shown that rats do not self-administer psilocybin - a standard test for abuse liability - and users develop rapid tolerance that makes compulsive use essentially self-limiting.

The Path Forward

Psilocybin businesses have a credible, evidence-based argument that 280E should not apply to their operations. The legal framework exists, the scientific evidence is strong, and the precedents being established in the cannabis context create additional pathways for challenge. The question is not whether these arguments have merit - it is whether operators have the advisors and the resolve to pursue them.